Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
19.93
-0.63 (-3.06%)
At close: Dec 5, 2025, 4:00 PM EST
20.32
+0.39 (1.96%)
After-hours: Dec 5, 2025, 4:15 PM EST
Forte Biosciences Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Forte Biosciences stock ranges from a low of $61 to a high of $75. The average analyst price target of $67 forecasts a 236.18% increase in the stock price over the next year.
Price Target: $67.00 (+236.18%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Forte Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $65 | Buy | Initiates | $65 | +226.14% | Nov 25, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +206.07% | Nov 17, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $75 | Strong Buy | Initiates | $75 | +276.32% | Aug 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +206.07% | Aug 15, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +206.07% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.57
from -12.17
EPS Next Year
-3.67
from -4.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.20 | -2.86 | ||||
| Avg | -4.57 | -3.67 | ||||
| Low | -5.00 | -4.40 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.